Transcarent, Glen Tullman’s health tech unicorn, raises $126 million

Transcarent, the fast-moving company helmed by health tech investor and former Livongo CEO Glen Tullman, today announced $126 million in Series D funding valuing the company at $2.2 billion.

The investment round was led by venture capital giant General Catalyst and 7wireVentures, where Tullman is a managing partner. Transcarent will use the funding to support development of artificial intelligence capabilities across the enterprise, growing its business, and pursuing acquisitions, Tullman told STAT. Transcarent has raised about $450 million to date.

Founded in 2020, Transcarent is one of a handful of upstarts hoping to use technology to improve care and lower costs for companies that provide health benefits for their workers. Tullman has said Transcarent is distinct from other health care navigation and virtual care companies that also promise to make care cheaper and more accessible.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In